COMPOSITIONS AND METHODS OF TREATING CANCER

The invention is directed to methods of treating cancer in subjects with a combination comprising a CCR2/5 dual antagonist, such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazol o[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexy l)acetamide; a monoclonal antibody, suc...

Full description

Saved in:
Bibliographic Details
Main Authors WEE Susan, GURURAJAN Murali, ZHAO Qihong, FARGNOLI Joseph
Format Patent
LanguageEnglish
Spanish
Published 09.09.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention is directed to methods of treating cancer in subjects with a combination comprising a CCR2/5 dual antagonist, such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazol o[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexy l)acetamide; a monoclonal antibody, such as nivolumab; and/or chemotherapy. La invención está dirigida a los métodos para tratar el cáncer en sujetos con una combinación que comprende un antagonista doble de CCR2/5, tal como la N-((1R,2S,5R)-5- (terc-butilamino)-2-((S)-3-(7 -terc-butilpirazolo[1,5- a][1,3,5]triazin-4-ilamino)-2-oxopirrolid in-1- il)ciclohexil)acetamida; un anticuerpo monoclonal, tal como el nivolumab; y/o quimioterapia.
Bibliography:Application Number: MX20200007526